CARA VS CASI Stock Comparison
Performance
CARA10/100
10/100
CARA returned -89.02% in the last 12 months. Based on SPY's performance of -20.58%, its performance is below average giving it a score of 10 of 100.
CASI100/100
100/100
CASI returned 131.96% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.
Analyst Price Targets
CARA79/100
79/100
7 analysts offer 12-month price targets for CARA. Together, they have an average target of 28, the most optimistic target put CARA at 30 within 12-months and the most pessimistic has CARA at 26.
CASI75/100
75/100
2 analysts offer 12-month price targets for CASI. Together, they have an average target of 12, the most optimistic target put CASI at 12 within 12-months and the most pessimistic has CASI at 12.
Sentiment
CARA67/100
67/100
CARA had a bullish sentiment score of 67.18% across Twitter and StockTwits over the last 12 months. It had an average of 7.42 posts, 3.60 comments, and 9.03 likes per day.
CASI
"Sentiment" not found for CASI
Technicals
CARA14/100
14/100
CARA receives a 14 of 100 based on 14 indicators. 2 are bullish, 12 are bearish.
CASI93/100
93/100
CASI receives a 92 of 100 based on 14 indicators. 12 are bullish, 0 are bearish.
Earnings
CARA10/100
10/100
CARA has missed earnings 6 times in the last 20 quarters.
CASI10/100
10/100
CASI has missed earnings 9 times in the last 20 quarters.
Profit
CARA10/100
10/100
Out of the last 20 quarters, CARA has had 1 profitable quarters and has increased their profits year over year on 1 of them.
CASI10/100
10/100
Out of the last 20 quarters, CASI has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
CARA41/100
41/100
CARA has had a lower than average amount of volatility over the last 12 months giving it a score of 40 of 100.
CASI60/100
60/100
CASI has had a higher than average amount of volatility over the last 12 months giving it a score of 60 of 100.
All score calculations are broken down here to help you make more informed investing decisions
Cara Therapeutics, Inc. Summary
Nasdaq / CARA
Healthcare
Biotechnology
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
CASI Pharmaceuticals, Inc. Ordinary Shares Summary
Nasdaq / CASI
Healthcare
Biotechnology
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare CARA to other companies in the same or a similar industry.